vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and DMC Global Inc. (BOOM). Click either name above to swap in a different company.
DMC Global Inc. is the larger business by last-quarter revenue ($143.5M vs $139.2M, roughly 1.0× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -7.8%, a 43.3% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -5.8%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $9.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -7.3%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
DMC Mining Services is a mining services contractor founded in 1980 operating in Canada, the United States, Chile, and Mongolia
ADMA vs BOOM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $143.5M |
| Net Profit | $49.4M | $-11.2M |
| Gross Margin | 63.8% | 17.1% |
| Operating Margin | 45.1% | -7.8% |
| Net Margin | 35.5% | -7.8% |
| Revenue YoY | 18.4% | -5.8% |
| Net Profit YoY | -55.9% | -3871.6% |
| EPS (diluted) | $0.20 | $-0.60 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $143.5M | ||
| Q3 25 | $134.2M | $151.5M | ||
| Q2 25 | $122.0M | $155.5M | ||
| Q1 25 | $114.8M | $159.3M | ||
| Q4 24 | $117.5M | $152.4M | ||
| Q3 24 | $119.8M | $152.4M | ||
| Q2 24 | $107.2M | $171.2M | ||
| Q1 24 | $81.9M | $166.9M |
| Q4 25 | $49.4M | $-11.2M | ||
| Q3 25 | $36.4M | $-3.1M | ||
| Q2 25 | $34.2M | $116.0K | ||
| Q1 25 | $26.9M | $677.0K | ||
| Q4 24 | $111.9M | $296.0K | ||
| Q3 24 | $35.9M | $-101.3M | ||
| Q2 24 | $32.1M | $4.0M | ||
| Q1 24 | $17.8M | $2.6M |
| Q4 25 | 63.8% | 17.1% | ||
| Q3 25 | 56.3% | 21.7% | ||
| Q2 25 | 55.1% | 23.6% | ||
| Q1 25 | 53.2% | 25.9% | ||
| Q4 24 | 53.9% | 20.8% | ||
| Q3 24 | 49.8% | 19.8% | ||
| Q2 24 | 53.6% | 27.1% | ||
| Q1 24 | 47.8% | 25.4% |
| Q4 25 | 45.1% | -7.8% | ||
| Q3 25 | 38.0% | 0.4% | ||
| Q2 25 | 35.1% | 2.5% | ||
| Q1 25 | 30.4% | 4.1% | ||
| Q4 24 | 32.6% | -0.5% | ||
| Q3 24 | 33.1% | -97.7% | ||
| Q2 24 | 36.6% | 6.8% | ||
| Q1 24 | 26.7% | 4.0% |
| Q4 25 | 35.5% | -7.8% | ||
| Q3 25 | 27.1% | -2.0% | ||
| Q2 25 | 28.1% | 0.1% | ||
| Q1 25 | 23.4% | 0.4% | ||
| Q4 24 | 95.2% | 0.2% | ||
| Q3 24 | 30.0% | -66.5% | ||
| Q2 24 | 29.9% | 2.3% | ||
| Q1 24 | 21.7% | 1.5% |
| Q4 25 | $0.20 | $-0.60 | ||
| Q3 25 | $0.15 | $-0.10 | ||
| Q2 25 | $0.14 | $-0.24 | ||
| Q1 25 | $0.11 | $0.04 | ||
| Q4 24 | $0.45 | $-0.18 | ||
| Q3 24 | $0.15 | $-8.27 | ||
| Q2 24 | $0.13 | $0.24 | ||
| Q1 24 | $0.08 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $31.9M |
| Total DebtLower is stronger | $72.1M | $50.6M |
| Stockholders' EquityBook value | $477.3M | $242.1M |
| Total Assets | $624.2M | $635.8M |
| Debt / EquityLower = less leverage | 0.15× | 0.21× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $31.9M | ||
| Q3 25 | $61.4M | $26.4M | ||
| Q2 25 | $90.3M | $12.4M | ||
| Q1 25 | $71.6M | $14.7M | ||
| Q4 24 | $103.1M | $14.3M | ||
| Q3 24 | $86.7M | $14.5M | ||
| Q2 24 | $88.2M | $14.6M | ||
| Q1 24 | $45.3M | $20.4M |
| Q4 25 | $72.1M | $50.6M | ||
| Q3 25 | $72.4M | $56.5M | ||
| Q2 25 | — | $58.7M | ||
| Q1 25 | — | $72.4M | ||
| Q4 24 | $72.3M | $70.8M | ||
| Q3 24 | — | $74.2M | ||
| Q2 24 | — | $84.1M | ||
| Q1 24 | — | $88.0M |
| Q4 25 | $477.3M | $242.1M | ||
| Q3 25 | $431.2M | $253.0M | ||
| Q2 25 | $398.3M | $253.9M | ||
| Q1 25 | $373.4M | $253.9M | ||
| Q4 24 | $349.0M | $251.0M | ||
| Q3 24 | $231.9M | $256.5M | ||
| Q2 24 | $188.3M | $416.0M | ||
| Q1 24 | $153.7M | $409.9M |
| Q4 25 | $624.2M | $635.8M | ||
| Q3 25 | $568.7M | $644.1M | ||
| Q2 25 | $558.4M | $645.0M | ||
| Q1 25 | $510.6M | $670.6M | ||
| Q4 24 | $488.7M | $671.3M | ||
| Q3 24 | $390.6M | $702.0M | ||
| Q2 24 | $376.4M | $869.5M | ||
| Q1 24 | $350.9M | $860.0M |
| Q4 25 | 0.15× | 0.21× | ||
| Q3 25 | 0.17× | 0.22× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | 0.21× | 0.28× | ||
| Q3 24 | — | 0.29× | ||
| Q2 24 | — | 0.20× | ||
| Q1 24 | — | 0.21× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $15.2M |
| Free Cash FlowOCF − Capex | $34.6M | $9.6M |
| FCF MarginFCF / Revenue | 24.8% | 6.7% |
| Capex IntensityCapex / Revenue | 0.8% | 3.9% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $37.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $15.2M | ||
| Q3 25 | $13.3M | $18.6M | ||
| Q2 25 | $21.1M | $15.2M | ||
| Q1 25 | $-19.7M | $4.5M | ||
| Q4 24 | $50.2M | $11.8M | ||
| Q3 24 | $25.0M | $19.0M | ||
| Q2 24 | $45.6M | $2.3M | ||
| Q1 24 | $-2.2M | $13.4M |
| Q4 25 | $34.6M | $9.6M | ||
| Q3 25 | $-1.1M | $14.4M | ||
| Q2 25 | $18.7M | $12.3M | ||
| Q1 25 | $-24.4M | $709.0K | ||
| Q4 24 | $47.5M | $6.1M | ||
| Q3 24 | $24.0M | $12.9M | ||
| Q2 24 | $43.6M | $-204.0K | ||
| Q1 24 | $-4.6M | $10.5M |
| Q4 25 | 24.8% | 6.7% | ||
| Q3 25 | -0.8% | 9.5% | ||
| Q2 25 | 15.3% | 7.9% | ||
| Q1 25 | -21.2% | 0.4% | ||
| Q4 24 | 40.4% | 4.0% | ||
| Q3 24 | 20.0% | 8.5% | ||
| Q2 24 | 40.7% | -0.1% | ||
| Q1 24 | -5.6% | 6.3% |
| Q4 25 | 0.8% | 3.9% | ||
| Q3 25 | 10.7% | 2.8% | ||
| Q2 25 | 2.0% | 1.9% | ||
| Q1 25 | 4.1% | 2.4% | ||
| Q4 24 | 2.3% | 3.7% | ||
| Q3 24 | 0.9% | 4.0% | ||
| Q2 24 | 1.9% | 1.5% | ||
| Q1 24 | 2.9% | 1.8% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | 131.43× | ||
| Q1 25 | -0.73× | 6.63× | ||
| Q4 24 | 0.45× | 39.90× | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | 0.58× | ||
| Q1 24 | -0.12× | 5.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
BOOM
| Dyna Energetics Segment | $68.9M | 48% |
| Other | $57.0M | 40% |
| Nobel Clad Segment | $17.7M | 12% |
